Phase 2 N=176 CAndesartan vs LIsinopril Effects on the BRain
Hypertension · Mild Cognitive Impairment
Primary: Executive Function — 87.23; 111.37 seconds
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=170 A Randomized, Double-blind Placebo-Controlled Pharmacogenetic Study of Topiramate in European-American Heavy Drinkers
Alcoholism · Alcohol Use Disorder (AUD)
Primary: Frequency of Heavy Drinking Days by Medication Group (Timeline Follow Back Calendar). — 29.00; 41.25 Heavy drinking days
Phase 2 N=20 Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung · Non-Small Cell Lung Cancer · Nonsmall Cell Lung Cancer
Primary: Response Rate (RR) — 3 Participants
Phase 3 N=65 Patient-Directed Postoperative Opioid Prescribing for Gynecologic Surgery
Gynecology · Surgery · Opioid Use
Primary: # of Opioid Pills Consumed — 26.7; 38.4 % oxycodone used
N/A N=30 LifeFlow Fluid Study- Non- Critical Pediatric Patients Having a Trans Abdominal Ultrasound
Dehydration in Children · Dehydration
Primary: Duration- Ultrasound Ordered to Completed — 154.4; 114.8 minutes
Phase 2 N=96 MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma
Clear-cell Metastatic Renal Cell Carcinoma
Primary: Progression-Free Survival (PFS) — 3.8; 3.6; 3.1 months — p==0.388
Phase 1 N=11 Biofeedback to Increase Propulsion During Walking After Stroke
Stroke
Primary: Change From Baseline in Forward Propulsion of the Paretic Limb From Pre- to Post-intervention — 0.00 Newtons . seconds/Body Weight — p=0.77
N/A N=70 A Psychological-behavioral Intervention to Increase Activity in Type 2 Diabetes
Type 2 Diabetes Mellitus
Primary: Number of PP-MI Sessions Completed by Participants — 11 sessions completed
N/A N=23 Variation in Urine Electrolytes, pH and Specific Gravity Throughout the Day
Healthy
Primary: Citrate/Creatinine Ratio — 0.658644; 0.584115; 0.562886; 0.540394 ratio
Phase 1 N=16 Glutathione and Function in HIV Patients
HIV Infection · Erythrocyte Glutathione Deficiency
Primary: Muscle Glutathione Concentration — 0.5; 2.2 micromol/g.Hb
N/A N=295 Involuntary Childlessness and Stress Management
Infertility
Primary: The Effect of Expressive Writing Intervention on Fertility Related Stress — 17.2; 15.7; 17.4; 17.1 units on a scale — p=<0.05
Phase 2 N=12 Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)
Advanced Solid Tumors · Carcinoid · Colorectal Cancer
Primary: Number of Participants With Adverse Events — 2; 1; 1; 1 Participants
N/A N=4 Leg Exercise During ECMO
Refractory Respiratory Failure
Primary: Time to Ambulation — 14.5; 15 days
N/A N=65 A Mobile Intervention to Improve Uptake of PrEP for Southern Black MSM
Hiv
Primary: Number of PrEP Services Appointments Attended-Full Sample — 0.58; 0.55 visits attended
Phase 1 N=29 Lorlatinib Renal Impairment Study
Renal Impairment
Primary: Area Under the Plasma Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) of Lorlatinib — 8329; 8683; 9890; 11760 ng*hr/mL